Back to search results

An Open-Label, Phase I, Multi-Center Study to Determine in Relapsed/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome or B-Cell Non-Hodgkin Lymphoma Patients the Recommended Dose of CYAD-02 After A Non-Myeloablative Preconditioning Chemotherapy Followed By A Potential CYAD-02 Consolidation Cycle for Non-Progressive Patients CYCLE-1 ? CYAD-02 NKG2D CAR-T Clinical dEvelopment

Brief Summary

Type:
Leukemias

Study Type:
Treatment

Phase:
I

ClinicalTrials.gov Identifier:
NCT04167696

Study #:
STUDY00144548

Start Date:
Mar 11, 2020

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT04167696

View Complete Trial Details & Eligibility at ClinicalTrials.gov